Sign up
SLDB

Solid Biosciences LLC (NASDAQ: SLDB)

Healthcare · Biotechnology

$6.35+0.12 (+1.93%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. SLDB rose 1.93% in the Nov 18 session to $6.35. Short interest is 20.53% of float with a 0.41% borrow fee. 11 active firms cover the stock as of Nov 19, 2026; 11 active firms with targets average $19.55 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumNeutral

RSI (14) 43.9 (overbought above 70, oversold below 30)

Trend—

—

Short interest20.5% of float

FINRA settlement Oct 30, 2026

SLDB price chart

Price $6.35 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$6.22Nov 18, 2026 session
Previous close
$6.23Nov 17, 2026 close
Day range
$6.08 – $6.43Nov 18, 2026 session
52-week range—
Volume
1.21MNov 18, 2026 session
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

SLDB · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18
Squeeze34Watch—
How the scores work →

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

Buy

0Strong Buy
11Buy
0Neutral
0Sell
0Strong Sell

Based on 11 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$12.00
Average$19.55
High$26.00

As of Nov 19, 2026 across 11 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q2 2026—−$0.38—
Q1 2026−$0.44−$0.52—
Annual 2025—−$1.99—
Q3 2025—−$0.48—
Q2 2025—−$0.42—
Q1 2025—−$0.59—
Annual 2024−$0.78−$3.06—
Q3 2024−$0.66−$0.79—

Smart-money activity

— · Smart-money activity not available

All smart-money activity →

News and press releases

All SLDB news →

Company profile

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy,

CEO
—
Headquarters
Charlestown, MA, United States
Employees
121
IPO date
Jan 26, 2018
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.